Zibotentan is under clinical development by AstraZeneca and currently in Phase II for Diabetic Nephropathy. According to GlobalData, Phase II drugs for Diabetic Nephropathy have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Zibotentan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zibotentan overview
Zibotentan is under development for the treatment of diabetic nephropathy, chronic kidney disease (CKD), cirrhosis with features of portal hypertension and microvascular angina. The drug candidate is administered orally in the form of tablet and capsule. It is a selective antagonist of the endothelin-A (ET-A) receptor with antineoplastic activity. It was also under development for intermittent claudication in peripheral artery disease, patients with non-metastatic castrate resistant prostate cancer, epithelial ovarian cancer, fallopian tube cancer, primary serous peritoneal cancer and non-small cell lung cancer .
AstraZeneca overview
AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
For a complete picture of Zibotentan’s drug-specific PTSR and LoA scores, buy the report here.